(MNPR) Monopar Therapeutics - Overview
Stock: Cancer Drug, Radio-Immuno, Radiotherapeutic, Diagnostic Agent
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 138% |
| Relative Tail Risk | -20.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | -1.67 |
| Character TTM | |
|---|---|
| Beta | 1.384 |
| Beta Downside | 1.303 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.19% |
| CAGR/Max DD | 0.51 |
Description: MNPR Monopar Therapeutics January 02, 2026
Monopar Therapeutics (NASDAQ: MNPR) is a U.S.-based, clinical-stage biotech focused on oncology, developing an oral small-molecule (ALXN1840) and a suite of radio-immunoconjugates built on its proprietary humanized antibody MNPR-101, which targets the urokinase-type plasminogen activator receptor (uPAR) expressed on many solid tumors. The pipeline includes a late-stage oral candidate, a radiodiagnostic (MNPR-101-Zr), a radiotherapeutic in pre-clinical development (MNPR-101-Lu), and collaborations with NorthStar on radio-immunotherapies for severe COVID-19.
Key quantitative points (as of Q3 2024): • Cash and cash equivalents ≈ $78 million, giving a runway of roughly 12-15 months at the current burn rate of $6-7 million per quarter. • ALXN1840 received Fast Track designation from the FDA in 2023, which historically accelerates review timelines for oncology drugs. • The global market for uPAR-targeted therapies is estimated at $1.2 billion by 2028, driven by rising incidence of solid tumors and increasing adoption of theranostic approaches. These drivers suggest that successful trial read-outs could materially shift the company’s valuation, but the outcomes remain highly uncertain.
For a deeper, data-rich analysis of MNPR’s valuation assumptions and scenario modeling, you might find ValueRay’s platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA 90.55 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.08 > 3% & CFO -10.8m > Net Income -19.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 56.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.12m) vs 12m ago -37.96% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -2.65 > 6 (EBITDA TTM -20.0m / Interest Expense TTM -11.8m) |
Altman Z'' -15.00
| A: 0.98 (Total Current Assets 144.1m - Total Current Liabilities 2.57m) / Total Assets 144.2m |
| B: -0.58 (Retained Earnings -84.3m / Total Assets 144.2m) |
| C: -0.42 (EBIT TTM -31.3m / Avg Total Assets 75.1m) |
| D: -31.93 (Book Value of Equity -84.3m / Total Liabilities 2.64m) |
| Altman-Z'' Score: -31.79 = D |
What is the price of MNPR shares?
Over the past week, the price has changed by -4.36%, over one month by -5.43%, over three months by -28.49% and over the past year by +22.59%.
Is MNPR a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MNPR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112 | 93.9% |
| Analysts Target Price | 112 | 93.9% |
| ValueRay Target Price | 62.6 | 8.4% |
MNPR Fundamental Data Overview February 05, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -31.3m USD
EBITDA TTM = -20.0m USD
Long Term Debt = 70.9k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 31.4k USD (from shortTermDebt, last quarter)
Debt = 102.2k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -127.6m USD (from netDebt column, last quarter)
Enterprise Value = 303.4m USD (447.0m + Debt 102.2k - CCE 143.7m)
Interest Coverage Ratio = -2.65 (Ebit TTM -31.3m / Interest Expense TTM -11.8m)
EV/FCF = -28.02x (Enterprise Value 303.4m / FCF TTM -10.8m)
FCF Yield = -3.57% (FCF TTM -10.8m / Enterprise Value 303.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.10 (Enterprise Value 303.4m / Total Assets 144.2m)
Interest Expense / Debt = 88.51% (Interest Expense 90.5k / Debt 102.2k)
Taxrate = 21.0% (US default 21%)
NOPAT = -24.7m (EBIT -31.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 56.10 (Total Current Assets 144.1m / Total Current Liabilities 2.57m)
Debt / Equity = 0.00 (Debt 102.2k / totalStockholderEquity, last quarter 141.6m)
Debt / EBITDA = 6.37 (negative EBITDA) (Net Debt -127.6m / EBITDA -20.0m)
Debt / FCF = 11.78 (negative FCF - burning cash) (Net Debt -127.6m / FCF TTM -10.8m)
Total Stockholder Equity = 75.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.88% (Net Income -19.4m / Total Assets 144.2m)
RoE = -25.72% (Net Income TTM -19.4m / Total Stockholder Equity 75.6m)
RoCE = -41.30% (EBIT -31.3m / Capital Employed (Equity 75.6m + L.T.Debt 70.9k))
RoIC = -32.66% (negative operating profit) (NOPAT -24.7m / Invested Capital 75.6m)
WACC = 11.02% (E(447.0m)/V(447.1m) * Re(11.02%) + (debt cost/tax rate unavailable))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -30.86%
Fair Price DCF = unknown (Cash Flow -10.8m)
EPS Correlation: -42.47 | EPS CAGR: -2.93% | SUE: -0.10 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.72 | Chg30d=+0.018 | Revisions Net=+1 | Analysts=10
EPS next Year (2026-12-31): EPS=-3.48 | Chg30d=-0.032 | Revisions Net=+1 | Growth EPS=-108.2% | Growth Revenue=+0.0%